~~<i id='81B227AEF1'><strike id='81B227AEF1'><tt id='81B227AEF1'><pre id='81B227AEF1'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：leisure time 2025-09-28 12:24:18 Page View：24934

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Why Charlie Gard's case is so disturbing to Americans
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

California Joshua trees severely burned in massive wildfire

1:35AJoshuaTreeburnsduringtheYorkFire,July30,2023,intheMojaveNationalPreserve,Calif.TyO'neil/APCalif

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

AI can decode, harness the power of the humane immune system

AdobeIftheCovid-19pandemichasshownusonething,itishowlittlewereallyknowabouthowthehumanimmunesystemwo